X0306 4 2021-02-01 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2021-02-01 4 M 0 5000 12.21 A 5000 D Common Stock 2021-02-01 4 S 0 400 156.16 D 4600 D Common Stock 2021-02-01 4 S 0 800 157.28 D 3800 D Common Stock 2021-02-01 4 S 0 400 158.28 D 3400 D Common Stock 2021-02-01 4 S 0 800 159.20 D 2600 D Common Stock 2021-02-01 4 S 0 300 160.33 D 2300 D Common Stock 2021-02-01 4 S 0 300 162.00 D 2000 D Common Stock 2021-02-01 4 S 0 300 163.07 D 1700 D Common Stock 2021-02-01 4 S 0 600 164.20 D 1100 D Common Stock 2021-02-01 4 S 0 200 165.32 D 900 D Common Stock 2021-02-01 4 S 0 100 171.30 D 800 D Common Stock 2021-02-01 4 S 0 700 172.86 D 100 D Common Stock 2021-02-01 4 S 0 100 174.00 D 0 D Stock Option (Right to Buy) 12.21 2021-02-01 4 M 0 5000 0 D 2027-10-03 Common Stock 5000 169952 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.61 to $156.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.85 to $157.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.88 to $158.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.89 to $159.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.91 to $160.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to 162.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.80 to $164.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.30 to $165.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.40 to $173.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). /s/ Lori Henderson, as Attorney-in-Fact 2021-02-02